508-77-0
Chemical Structure
Cymarin
- CAS No.: 508-77-0
- Formula:C30H44O9
- Molecular Weight:548.66
IUPAC Name: (3S,5S,8R,9S,10S,13R,14S,17R)-5,14-dihydroxy-3-(((2R,4S,5R,6R)-5-hydroxy-4-methoxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-13-methyl-17-(5-oxo-2,5-dihydrofuran-3-yl)hexadecahydro-10H-cyclopenta[a]phenanthrene-10-carbaldehyde
InChIKey: XQCGNURMLWFQJR-ZNDDOCHDSA-N
SMILES: O=C[C@@]12[C@]3([H])[C@](CC[C@@]1(C[C@@H](O[C@@]4([H])C[C@@H]([C@H](O)[C@@H](C)O4)OC)CC2)O)([H])[C@@]5([C@@](C)([C@@H](C(CO6)=CC6=O)CC5)CC3)O
Biological Activity:
Cymarin, a cardiac glycoside, potently inhibits the Palytoxin (PTX)-induced K+ release (IC50=0.42 μM). Cymarin reveals an antitumor activity against breast cancer and pancreatic cancer. Cymarin exhibits antifeedant and growth inhibitory effects as crop protectant[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Cymarin | 97.28% | Cymarin, a cardiac glycoside, potently inhibits the Palytoxin (PTX)-induced K+ release (IC50=0.42 μM). Cymarin reveals an antitumor activity against breast cancer and pancreatic cancer. Cymarin exhibits antifeedant and growth inhibitory effects as crop protectant. |
||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Ozaki H, et al. Interaction of palytoxin and cardiac glycosides on erythrocyte membrane and (Na+ + K+) ATPase. Eur J Biochem. 1985;152(2):475-480. [Content Brief]
- [2]. Li Q, et al., Translation of paired box 6 (PAX6) mRNA is IRES-mediated and inhibited by cymarin in breast cancer cells. Genes Genet Syst. 2023 Oct 24;98(4):161-169. [Content Brief]
- [3]. Akhtar Y, et al., Comparative growth inhibitory and antifeedant effects of plant extracts and pure allelochemicals on four phytophagous insect species. J Applied Entomology. 10 February 2004.128,32-38.
- [4]. Tan L, et al., A targetable pathway to eliminate TRA-1-60+/TRA-1-81+ chemoresistant cancer cells. J Mol Cell Biol. 2023 Nov 27;15(6):mjad039. [Content Brief]
